What is Zacks Research’s Forecast for CRL FY2027 Earnings?

Charles River Laboratories International, Inc. (NYSE:CRL) – Zacks Research issued their FY2027 earnings estimates for shares of Charles River Laboratories International in a report released on Wednesday, March 12th. Zacks Research analyst R. Department anticipates that the medical research company will post earnings of $11.39 per share for the year. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $9.36 per share.

Other equities analysts have also issued research reports about the stock. Barclays decreased their price target on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 18th. UBS Group restated a “neutral” rating and set a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. JPMorgan Chase & Co. reduced their target price on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a report on Thursday, February 20th. Citigroup upgraded shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and lifted their target price for the company from $155.00 to $175.00 in a report on Tuesday, March 4th. Finally, Redburn Atlantic upgraded shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 target price on the stock in a report on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, Charles River Laboratories International presently has an average rating of “Hold” and an average price target of $198.36.

Charles River Laboratories International Stock Up 2.6 %

Shares of CRL opened at $171.27 on Friday. The firm has a market cap of $8.76 billion, a PE ratio of 1,141.78, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The company’s fifty day moving average is $167.74 and its two-hundred day moving average is $184.59. Charles River Laboratories International has a fifty-two week low of $150.79 and a fifty-two week high of $274.77. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. Charles River Laboratories International’s revenue for the quarter was down 1.1% on a year-over-year basis. During the same quarter last year, the business earned $2.46 EPS.

Institutional Investors Weigh In On Charles River Laboratories International

A number of institutional investors have recently modified their holdings of CRL. Principal Financial Group Inc. grew its position in shares of Charles River Laboratories International by 3.6% during the 3rd quarter. Principal Financial Group Inc. now owns 60,501 shares of the medical research company’s stock valued at $11,917,000 after buying an additional 2,126 shares during the last quarter. Assetmark Inc. grew its position in shares of Charles River Laboratories International by 1,153.3% during the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after buying an additional 173 shares during the last quarter. Covestor Ltd grew its position in shares of Charles River Laboratories International by 40.9% during the 3rd quarter. Covestor Ltd now owns 327 shares of the medical research company’s stock valued at $65,000 after buying an additional 95 shares during the last quarter. Apollon Wealth Management LLC bought a new position in Charles River Laboratories International in the 3rd quarter worth about $201,000. Finally, Sumitomo Mitsui Trust Group Inc. grew its position in Charles River Laboratories International by 3.4% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 111,995 shares of the medical research company’s stock worth $22,060,000 after purchasing an additional 3,714 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

Insider Transactions at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 4,400 shares of the business’s stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the sale, the executive vice president now owns 20,013 shares of the company’s stock, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Birgit Girshick bought 1,514 shares of the company’s stock in a transaction dated Thursday, February 20th. The stock was bought at an average cost of $164.63 per share, with a total value of $249,249.82. Following the transaction, the chief operating officer now directly owns 55,058 shares in the company, valued at approximately $9,064,198.54. The trade was a 2.83 % increase in their position. The disclosure for this purchase can be found here. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).